Abstract
The family Ganodermataceae comprising more than 200 fungal species is mainly distributed in the tropical and subtropical areas of Asia, Australia, Africa, and America [1] . More than 100 species of this family grow in China, of which 78 wild species were found in Hainan Province [2] . Ganoderma and Amauroderma are two genera of the Ganodermataceae family. A great deal of work has been carried out on the genus Ganoderma [3] . Two of its species, recorded in the Chinese Pharmacopoeia, G. lucidum and G. sinense, have been used for the treatment of migraine, hypertension, arthritis, bronchitis, asthma, gastritis, diabetes, nephritis, and hepatitis problems for centuries [4, 5] . Recent research on the chemical constituents of Ganoderma species showed the presence of natural products including triterpenes, steroid, alkaloids, flavonoids, polysaccharides, and fatty acids [6] [7] [8] . Previous screening of acetylcholinesterase (AChE) inhibitors from fungal extracts showed that many fungi, including the genera of the Ganodermataceae family, exhibited inhibitory activities against AChE [9] . At present, chemical constituents from many Amauroderma species, including Amauroderma amoiensis (Zhao) found in Fujian and Hainan Province of China [10] , and their biological activities are still not reported. In order to study the bioactive constituents of A. amoiensis, a chemical investigation was carried out and led to the isolation of one new compound, named amauroamoienin (1), along with thirteen known compounds (2-14) (l " Fig. 1 ), 4-hydroxy-17-methylincisterol (2) [11] , (l7R)-17-methylincisterol (3) [12] , 1,5-dihydroxy-6′,6′-dimethylpyrano[2′,3′:3,2] xanthone (4) [13] , jacareubin (5) [13] , ergosterol peroxide (6) [14] , ergosta-7,22-dien-3β-ol (7) [15, 16] , (22E,24R)-ergosta-8,22E-diene-3β,5α,6β,7α-tetraol (8) [17, 18] , 22E-7α-methoxy-5α,6α-epoxyergosta-8 (14),22-dien-3β-ol (9) [19] , 3β,5α,9α-trihydroxyergosta-7,22-dien-6-one (10) [20, 21] , 1H-indole-3-carboxylic acid (11) [22] , phydroxybenzoic acid (12) [23] , methyl 3,4-dihydroxybenzoate (13) [24] , and 7,8-dimethylalloxazine (14) [25] . Herein, we describe the isolation and structural elucidation of the new compound (1), as well as the AChE inhibitory activities of all isolates. Compound 1 was obtained as a yellow amorphous powder, and its molecular formula was assigned to be C 46 (5) [14] hinted that 1 had a xanthone moiety with the same structure of that of 5, which was also confirmed by olefinic and aromatic pro- C NMR data with those of (22E,24R)-ergosta-7,9(11),22-triene-3β,5α,6β-triol [26] suggested that they might have identical skeletons except for the difference of three oxygenated carbons. The key HMBC correlations from H-6 (δ H 4.73, s) to C-6′, C-7, and C-8 indicated that the steroid and xanthone moieties were connected via an oxygen at C-6 and C-6′, which also confirmed the epoxy group formed at two other oxygenated carbons. The HMBC correlation from H-19 (δ H 1.24, s) to C-5 (δ C 77.3) showed that the epoxy group was at C-4 and C-5. The stereochemistry of the chiral centers (C-10, C-13, C-14, C-17) and the side chain at C-20 and C-24 of the steroid moiety in 1 were proposed to be the same as those of (22E,24R)-ergosta-7,9(11),22-triene-3β,5α,6β-triol by comparison of the their 13 C NMR data, with the possible β-orientations of CH 3 -18 and CH 3 -19 and α-orientations of H-14 and H-17 [26] . The β-orientation of H-6 was determined by the key NOE of H-6/H-19 (l " Fig. 2 ). The weak correlations of H-6 and H-4 (δ H 3.93, m) with the same proton H-2b (δ H 1.61, m) proposed the β-orientation of H-4, which accordingly hinted the α-orientation of the epoxy group in 1. NOE of H-18/H-20 further confirmed the β-orientation of CH 3 -18 and the α-orientation of H-17. Thus, the structure of compound 1 was assigned as shown in l " Fig. 1 , and this compound was named amauroamoienin. The AChE inhibitory activities for compounds 1-11 were tested. The purities of all compounds were more than 98 % by HPLC analyses. Compound 3 showed a certain inhibitory activity (inhibition percentage was 46.33 %) at the concentration of 100 µM, and compounds 1 and 5 showed weak inhibitory activity (inhibition percentages were 14.63 % and 25.49 %, respectively) (l " Table 2) . Meanwhile, the other compounds were inactive with inhibition ratios less than 10 %. Bioassay of AChE inhibitory activity: Acetylcholinesterase inhibitory activity of all compounds was assayed by the spectrophoto- Table 1 1 H NMR (500 MHz) and 13 C NMR (125 MHz) data of compounds 1 and 5 in CDCl 3 (δ H in ppm, J in Hz). metric method developed by Ellman et al. [27] with slight modifications. S-Acetylthiocholine iodide, 5,5′-dithio-bis-(2-nitrobenzoic) acid (DTNB, Ellmanʼs reagent), and acetylcholinesterase derived from human erythrocytes were purchased from Sigma Chemical. Compounds were dissolved in DMSO. The reaction mixture (totally 200 µL), containing phosphate buffer (pH 8.0), test compound (50 µM), and acetylcholinesterase (0.02 U/mL), was incubated for 20 min (30°C). The reaction was initiated by the addition of 20 µL of DTNB (0.625 mM) and 20 µL acetylthiocholine iodide (0.625 mM) for the AChE inhibitory activity assay. The hydrolysis of acetylthiocholine was monitored at 405 nm after 30 min. Tacrine (Sigma-Aldrich 99 %) was used as a positive control with final concentration of 0.333 µM, and DMSO was used as negative control with final concentration of 0.1 %. All the reactions were performed in triplicate. The percentage of inhibition was calculated as follows: % inhibition = (E-S)/E × 100 (E is the activity of the enzyme without test compound and S is the activity of enzyme with test compounds).
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The original spectra of NMR and HREIMS data for the new compound (1) and general experimental procedures are available as Supporting Information. 
